Detalhe da pesquisa
1.
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Clin Infect Dis
; 76(3): e1177-e1185, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36164254
2.
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
J Antimicrob Chemother
; 78(11): 2702-2714, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726401
3.
Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
J Antimicrob Chemother
; 75(11): 3260-3268, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32780098
4.
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
Clin Microbiol Rev
; 31(4)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30158301
5.
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Clin Infect Dis
; 68(9): 1530-1538, 2019 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30188978